Director/PDMR Shareholding
Summary by AI BETAClose X
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
James Ford |
||||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
David Redfern |
||||
|
b) |
Position/status |
President, Corporate Development |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Victoria Whyte |
||||
|
b) |
Position/status |
SVP & Company Secretary |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GSK plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
||||
|
b) |
Nature of the transaction |
The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
|
e) |
Date of the transaction |
2025-11-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 2 hours ago Oxford Nanopore Technologies
- 2 hours ago AVI Global Trust
- 3 hours ago LSL Property Services
- 3 hours ago Bluebird Merchant Ventures (DI)
- 3 hours ago Power Probe PLC